In conclusion, our research supports the recent notion that mast-cells and its modulators (IL-6, IL-10 and IL-2) can be drugable targets in ALS and that compounds able to alter mast-cells pathogenic effects should be tested in different ALS murine models (80). Here, IL2 is linked to amyotrophic lateral sclerosis.